Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.
Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.
Clinical Pearls:
Ipilimumab is an immune modulator that works by breaking tolerance and stimulating the immune system so that it can recognize and attack the prostate cancer
Since ipilimumab is not specific to a cancer antigen, it causes side effects that are related to an overactive immune system
The analysis of the trial found that the side effect profile of ipilimumab in prostate cancer is similar to what was previously described in melanoma, where the drug is approved
Standard approaches to the management of these side effects are almost always effective
